{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:10:32Z","timestamp":1776193832920,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patients with treated solid tumors (TST) are a highly heterogeneous and difficult-to-treat population due to the risk of disease progression\/recurrence or infection. Methods: We conducted an observational, retrospective, single-center study at the Dermatology Clinic of Turin with a focus on the special population of cancer patients with psoriasis treated with biologics. Results: As of July 2023, 52 psoriatic patients with a prior\/concomitant history of malignancy had taken biologic drugs. The median age was 67 years, and the median age of cancer onset was 55 years. The most common tumors were gastrointestinal cancer and melanoma. After the tumor diagnosis, 61% received an anti-IL17 drug; 37 patients continued the initiated biologic therapy, while 12 switched drugs due to secondary inefficacy. The estimated biologic DS was 55.6% at 50 months. Evidence suggests that IL-17 is a key pathogenic factor involved in tumorigenesis, resulting in a lower risk of malignancies in subjects managed with IL-17 inhibitors. Similarly, IL-23 plays a role in suppressing innate immunity and promoting tumor and metastases development. This is a consistent real-life case series that support the use of biologic drugs in patients with TST. Conclusions: IL-23 and IL-17 inhibitors, being immunomodulators rather than immunosuppressants, may be a safe option for patients in an active oncological setting and for immune-correlated adverse events.<\/jats:p>","DOI":"10.3390\/jcm13216546","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T11:53:43Z","timestamp":1730462023000},"page":"6546","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-2139","authenticated-orcid":false,"given":"Nicole","family":"Macagno","sequence":"first","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Borriello","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Astrua","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Verrone","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Siliquini","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: Should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: Long-term safety in a single- center real-life population","volume":"33","author":"Valenti","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: Should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/jdv.19135","article-title":"Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients","volume":"37","author":"Mastorino","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3892\/ijo_00000620","article-title":"IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity","volume":"36","author":"Fukuda","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.3390\/ijms12117424","article-title":"Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients","volume":"12","author":"He","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_12","first-page":"9647","article-title":"Activation of the TLR4\/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A","volume":"15","author":"Kang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chyuan, I.-T., and Lai, J.-H. (2020). New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem. Pharmacol., 175.","DOI":"10.1016\/j.bcp.2020.113928"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J. Der Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug Survival of IL-12\/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study","volume":"22","author":"Torres","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e14889","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6546\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:00Z","timestamp":1760113500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":20,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216546"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216546","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}